Litcius/Paper detail

PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

Rui-Nan Zhang, Feng Shen, Qin Pan, Haixia Cao, Guangyu Chen, Jian‐Gao Fan

2021World Journal of Gastroenterology33 citationsDOIOpen Access PDF

Abstract

BACKGROUND: The association between PPARGC1A rs8192678 and nonalcoholic fatty liver disease (NAFLD) requires further confirmation. In addition, it is still unknown whether PPARGC1A rs8192678 is associated with hepatic histological features in NAFLD in the Chinese population. AIM: To investigate the interaction between PPARGC1A rs8192678 and nonalcoholic steatohepatitis (NASH), and whether this polymorphism is associated with hepatic histological features. METHODS: Fifty-nine patients with liver biopsy-proven NAFLD and 93 healthy controls were recruited to a cohort representing the Chinese Han population. The SAF (steatosis, activity, and fibrosis) scoring system was used for hepatic histopathological evaluation. The polymorphisms of PPARGC1A rs8192678 and patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 were genotyped. The intrahepatic mRNA expression of PPARGC1A was evaluated by real-time polymerase chain reaction. RESULTS: = 0.014). CONCLUSION: The PPARGC1A rs8192678 risk A allele is associated with NAFLD, and with S2-3, A ≥ 2 and NASH in NAFLD patients, independent of PNPLA3 rs738409, and may be associated with nonobese NASH.

Topics & Concepts

Nonalcoholic fatty liver diseasePPARGC1AInternal medicineGastroenterologyMedicineOdds ratioSteatohepatitisSteatosisPopulationFatty liverBiologyDiseaseGeneticsGeneCoactivatorEnvironmental healthTranscription factorLiver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated ReceptorsLiver Diseases and Immunity